Please Wait.....
Report
Chronic Refractory Cough (CRC) - Epidemiology Forecast - 2032
Market Report I 2022-08-01 I 77 Pages I DelveInsight
DelveInsight's 'Chronic Refractory Cough - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Chronic Refractory Cough Disease Understanding
Chronic Refractory Cough (CRC) is defined as a cough lasting more than 8 weeks despite guidelines-based treatment and which may be treated only by different medical specialties. Individuals with CRC have impaired quality of life and interruption of activities of daily living. It also results in depression and can persist for many months or years, despite systematic investigation and treatment of known causes. The infection can also be referred to as chronic cough (CC), chronic idiopathic cough (CIC), unexplained chronic cough (UCC), and cough hypersensitivity syndrome (CHS).
Recurrent incidence of CC results in CRC. The symptoms and indications of CRC are similar to those of CC. One of the first and most important symptoms that may indicate respiratory involvement is a persistent or chronic cough. Key symptoms include a dry irritating cough localized around the laryngeal region. Symptoms are not restricted to cough and can include globus, dyspnea, and dysphonia. CRC has factors in common with laryngeal hypersensitivity syndromes and chronic pain syndromes, and these similarities help to shed light on the pathophysiology of the condition.
Laryngopharyngeal reflux (LPR) is a common cause of CRC and may be present without symptoms of classic GERD, including heartburn (silent reflux). Obstructive sleep apnoea syndrome (OSAS) is also an independent risk factor for CC and a risk factor for LPR/GERD recalcitrant to medical therapy. ACE inhibitors are another common cause of CRC, which can occur spontaneously even after many years on this medication without previous problems.
CC is more prevalent in women, and there are various complications associated with it which include negative psychological, social, and physical outcomes. It causes an interruption of daily activities, social embarrassment, and physical exhaustion secondary to frequent coughing episodes.
Chronic Refractory Cough Diagnosis
CRC can be diagnosed when patients have no identified causes of CC or when the cough persists after investigation and treatment of cough-related conditions.
The diagnosis of the disease is either done by primary or secondary assessment. The initial assessment for protracted or chronic cough is intended to characterize the condition based on history, elicit any alarm symptoms or findings that may indicate a serious underlying disease, and identify whether there is a specific disease present that is associated with CC.
The first step in evaluating individuals with CRC is performing a correct and complete anamnesis, followed by a physical examination. While the second stage of investigation is considered to further characterize the condition of the disease. These include nasendoscopy and 24-hour pH monitoring. Laryngeal examination using flexible nasendoscopy identifies the presence of laryngeal lesions or abnormal motor patterns that might be contributing to the cough symptoms and laryngeal discomfort.
Some of the common tests that are performed to examine chronic cough are chest radiograph, spirometric and peak expiratory flow measurements, bronchoprovocation testing, sinus imaging, etc.
Continued in the report..
Chronic Refractory Cough Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by 12-month Prevalent Cases of Chronic Cough, Gender-specific Cases of Chronic Cough, Total Diagnosed Prevalent Cases of Chronic Refractory Cough, and Diagnosed Prevalent Cases of Chronic Cough in Idiopathic Pulmonary Fibrosis scenario of CRC in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Chronic Refractory Cough Detailed Epidemiology Segmentation
- In 2021, the 12-month prevalent cases of CC were estimated to be 30,625,209 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019-2032).
- Among the 7MM, the United States accounted for nearly 42% of the 12-month prevalent cases of CC with 12,782,168 cases in 2021 which are expected to increase further by 2032.
- Assessments as per DelveInsight's analysts show that the total diagnosed prevalent cases of CRC in the 7MM were 12,250,084 cases in 2021. Among the 7MM, in 2021, the US accounted for nearly 41.7% of the total diagnosed prevalent cases of CRC. The prevalent population for CRC was derived from the prevalent patient pool of CC.
- In the US, the gender-specific cases of CC were 5,061,738 and 7,720,429 cases for males and females, respectively in the year 2021, which are expected to increase by 2032.
- Among the EU-5, Germany accounted for the highest number of total diagnosed prevalent cases of CRC (1,383,684), followed by Italy with 1,034,973 cases in 2021. In contrast, Spain accounted for the least of the total diagnosed prevalent cases of CRC in the EU-5.
- In 2021, Japan accounted for 1,812,612 cases of total diagnosed prevalent cases of CRC, which is approximately 15% of the 7MM total diagnosed prevalent cases of CRC.
- In the US, the diagnosed prevalent cases of CC in IPF were 75,537 cases in 2021 which are expected to increase by 2032.
Scope of the Report
- The report covers a descriptive overview of Chronic Refractory Cough, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden of Chronic Refractory Cough.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for the 7MM, 12-month Prevalent Cases of Chronic Cough, Gender-specific Cases of Chronic Cough, Total Diagnosed Prevalent Cases of Chronic Refractory Cough, and Diagnosed Prevalent Cases of Chronic Cough in Idiopathic Pulmonary Fibrosis.
Report Highlights
- 11-Year Forecast of Chronic Refractory Cough
- The 7MM Coverage
- 12-month Prevalent Cases of Chronic Cough
- Gender-specific Cases of Chronic Cough
- Total Diagnosed Prevalent Cases of Chronic Refractory Cough
- Diagnosed Prevalent Cases of Chronic Cough in Idiopathic Pulmonary Fibrosis
Key Questions Answered
- What are the disease risk and burdens of Chronic Refractory Cough?
- What is the historical Chronic Refractory Cough patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Chronic Refractory Cough at the 7MM level?
- What will be the growth opportunities across the 7MM concerning the patient population with Chronic Refractory Cough?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Refractory Cough during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to buy
The Chronic Refractory Cough report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM Chronic Refractory Cough epidemiology forecast.
- The Chronic Refractory Cough epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
- The Chronic Refractory Cough epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
1. Key Insights
2. Report Introduction
3. CRC Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of CRC in 2019
3.2. Patient Share (%) Distribution of CRC in 2032
4. Executive Summary of CRC Epidemiology
5. Disease Background and Overview
5.1. Introduction to CRC
5.2. Signs and Symptoms
5.3. Causes
5.3.1. Upper Airway Cough Syndrome (UACS)
5.3.2. Asthma and COPD
5.3.3. Non-asthmatic Eosinophilic Bronchitis
5.3.4. Gastroesophageal/Laryngopharyngeal Reflux Disease
5.4. Risk factors
5.5. Mechanism of CC
5.6. Pathophysiology of CC
5.6.1. Similarity between CRC and other neuropathic disorders
5.6.2. Pathogenesis of CRS
5.7. Clinical features of CRC
5.8. Diagnosis
5.8.1. Primary assessment
5.8.2. Secondary assessment
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Assumptions and Rationale: the 7MM
6.3.1. 12-month Prevalent Cases of CC
6.3.2. Gender-specific Cases of CC
6.3.3. Diagnosed Prevalent Cases of CRC
6.3.4. Diagnosed prevalent population of CC in IPF
6.4. 12-month Prevalent Cases of CC in the 7MM
6.5. Total Diagnosed Prevalent Cases of CRC in the 7MM
6.6. The United States
6.6.1. 12-month Prevalent Cases of CC in the US
6.6.2. Gender-specific Cases of CC in the US
6.6.3. Total Diagnosed Prevalent Cases of CRC in the US
6.6.4. Diagnosed Prevalent Cases of CC in IPF in the US
6.7. The Five Major European Countries
6.7.1. 12-month Prevalent Cases of CC in the EU-5
6.7.2. Gender-specific Cases of CC in the EU-5
6.7.3. Total Diagnosed Prevalent Cases of CRC in the EU-5
6.7.4. Diagnosed Prevalent Cases of CC in IPF in the EU-5
6.7.5. Germany
6.7.5.1. 12-month Prevalent Cases of CC in Germany
6.7.5.2. Gender-specific Cases of CC in Germany
6.7.5.3. Total Diagnosed Prevalent Cases of CRC in Germany
6.7.5.4. Diagnosed Prevalent Cases of CC in IPF in Germany
6.7.6. France
6.7.6.1. 12-month Prevalent Cases of CC in France
6.7.6.2. Gender-specific Cases of CC in France
6.7.6.3. Total Diagnosed Prevalent Cases of CRC in France
6.7.6.4. Diagnosed Prevalent Cases of CC in IPF in France
6.7.7. Italy
6.7.7.1. 12-month Prevalent Cases of CC in Italy
6.7.7.2. Gender-specific Cases of CC in Italy
6.7.7.3. Total Diagnosed Prevalent Cases of CRC in Italy
6.7.7.4. Diagnosed Prevalent Cases of CC in IPF in Italy
6.7.8. Spain
6.7.8.1. 12-month Prevalent Cases of CC in Spain
6.7.8.2. Gender-specific Cases of CC in Spain
6.7.8.3. Total Diagnosed Prevalent Cases of CRC in Spain
6.7.8.4. Diagnosed Prevalent Cases of CC in IPF in Spain
6.7.9. The United Kingdom
6.7.9.1. 12-month Prevalent Cases of CC in the UK
6.7.9.2. Gender-specific Cases of CC in the UK
6.7.9.3. Total Diagnosed Prevalent Cases of CRC in the UK
6.7.9.4. Diagnosed Prevalent Cases of CC in IPF in the UK
6.8. Japan
6.8.1. 12-month Prevalent Cases of CC in Japan
6.8.2. Gender-specific Cases of CC in Japan
6.8.3. Total Diagnosed Prevalent Cases of CRC in Japan
6.8.4. Diagnosed Prevalent Cases of CC in IPF in Japan
7. Patient Journey
8. Key Opinion Leaders' Views
9. Appendix
9.1. Bibliography
9.2. Acronyms and Abbreviations
10. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
Table 1: Summary of CRC Epidemiology (2019-2032)
Table 2: Recommendations, strength and level of evidence, and supporting remarks for the diagnosis of CC in adults and children
Table 3: Comparison of cough guidelines in relation to CRC
Table 4: 12-month Prevalent Cases of CC in the 7MM, in Thousands (2019-2032)
Table 5: Total Diagnosed Prevalent Cases of CRC in the 7MM, in Thousands (2019-2032)
Table 6: 12-month Prevalent Cases of CC in the US, in Thousands (2019-2032)
Table 7: Gender-specific Cases of CC in the US, in Thousands (2019-2032)
Table 8: Total Diagnosed Prevalent Cases of CRC in the US, in Thousands (2019-2032)
Table 9: Diagnosed Prevalent Cases of CC in IPF in the US, in Thousands (2019-2032)
Table 10: 12-month Prevalent Cases of CC in the EU-5, in Thousands (2019-2032)
Table 11: Gender-specific Cases of CC in the EU-5, in Thousands (2019-2032)
Table 12: Total Diagnosed Prevalent Cases of CRC in the EU-5, in Thousands (2019-2032)
Table 13: Diagnosed Prevalent Cases of CC in IPF in the EU-5, in Thousands (2019-2032)
Table 14: 12-month Prevalent Cases of CC in Germany, in Thousands (2019-2032)
Table 15: Gender-specific Cases of CC in Germany, in Thousands (2019-2032)
Table 16: Total Diagnosed Prevalent Cases of CRC in Germany, in Thousands (2019-2032)
Table 17: Diagnosed Prevalent Cases of CC in IPF in Germany, in Thousands (2019-2032)
Table 18: 12-month Prevalent Cases of CC in France, in Thousands (2019-2032)
Table 19: Gender-specific Cases of CC in France, in Thousands (2019-2032)
Table 20: Total Diagnosed Prevalent Cases of CRC in France, in Thousands (2019-2032)
Table 21: Diagnosed Prevalent Cases of CC in IPF in France, in Thousands (2019-2032)
Table 22: 12-month Prevalent Cases of CC in Italy, in Thousands (2019-2032)
Table 23: Gender-specific Cases of CC in Italy, in Thousands (2019-2032)
Table 24: Total Diagnosed Prevalent Cases of CRC in Italy, in Thousands (2019-2032)
Table 25: Diagnosed Prevalent Cases of CC in IPF in Italy, in Thousands (2019-2032)
Table 26: 12-month Prevalent Cases of CC in Spain, in Thousands (2019-2032)
Table 27: Gender-specific Cases of CC in Spain, in Thousands (2019-2032)
Table 28: Total Diagnosed Prevalent Cases of CRC in Spain, in Thousands (2019-2032)
Table 29: Diagnosed Prevalent Cases of CC in IPF in Spain, in Thousands (2019-2032)
Table 30: 12-month Prevalent Cases of CC in the UK, in Thousands (2019-2032)
Table 31: Gender-specific Cases of CC in the UK, in Thousands (2019-2032)
Table 32: Total Diagnosed Prevalent Cases of CRC in the UK, in Thousands (2019-2032)
Table 33: Diagnosed Prevalent Cases of CC in IPF in the UK, in Thousands (2019-2032)
Table 34: 12-month prevalent cases of CC in Japan, in Thousands (2019-2032)
Table 35: Gender-specific Cases of CC in Japan, in Thousands (2019-2032)
Table 36: Total Diagnosed Prevalent Cases of CRC in Japan, in Thousands (2019-2032)
Table 37: Diagnosed Prevalent Cases of CC in IPF in Japan, in Thousands (2019-2032)
Figure 1: Symptoms of CRC
Figure 2: Origins and neurological pathways of the cough reflex.
Figure 3: 12-month Prevalent Cases of CC in the 7MM (2019-2032)
Figure 4: Total Diagnosed Prevalent Cases of CRC in the 7MM (2019-2032)
Figure 5: 12-month Prevalent Cases of CC in the US (2019-2032)
Figure 6: Gender-specific Cases of CC in the US (2019-2032)
Figure 7: Total Diagnosed Prevalent Cases of CRC in the US (2019-2032)
Figure 8: Diagnosed Prevalent Cases of CC in IPF in the US (2019-2032)
Figure 9: 12-month Prevalent Cases of CC in the EU-5 (2019-2032)
Figure 10: Gender-specific Cases of CC in the EU-5 (2019-2032)
Figure 11: Total Diagnosed Prevalent Cases of CRC in the EU-5 (2019-2032)
Figure 12: Diagnosed Prevalent Cases of CC in IPF in the EU-5 (2019-2032)
Figure 13: 12-month Prevalent Cases of CC in Germany (2019-2032)
Figure 14: Gender-specific Cases of CC in Germany (2019-2032)
Figure 15: Total Diagnosed Prevalent Cases of CRC in Germany (2019-2032)
Figure 16: Diagnosed Prevalent Cases of CC in IPF in Germany (2019-2032)
Figure 17: 12-month Prevalent Cases of CC in France (2019-2032)
Figure 18: Gender-specific Cases of CC in France (2019-2032)
Figure 19: Total Diagnosed Prevalent Cases of CRC in France (2019-2032)
Figure 20: Diagnosed Prevalent Cases of CC in IPF in France (2019-2032)
Figure 21: 12-month Prevalent Cases of CC in Italy (2019-2032)
Figure 22: Gender-specific Cases of CC in Italy (2019-2032)
Figure 23: Total Diagnosed Prevalent Cases of CRC in Italy (2019-2032)
Figure 24: Diagnosed Prevalent Cases of CC in IPF in Italy (2019-2032)
Figure 25: 12-month Prevalent Cases of CC in Spain (2019-2032)
Figure 26: Gender-specific Cases of CC in Spain (2019-2032)
Figure 27: Total Diagnosed Prevalent Cases of CRC in Spain (2019-2032)
Figure 28: Diagnosed Prevalent Cases of CC in IPF in Spain (2019-2032)
Figure 29: 12-month Prevalent Cases of CC in the UK (2019-2032)
Figure 30: Gender-specific Cases of CC in the UK (2019-2032)
Figure 31: Total Diagnosed Prevalent Cases of CRC in the UK (2019-2032)
Figure 32: Diagnosed Prevalent Cases of CC in IPF in the UK (2019-2032)
Figure 33: 12-month prevalent cases of CC in Japan (2019-2032)
Figure 34: Gender-specific Cases of CC in Japan (2019-2032)
Figure 35: Total Diagnosed Prevalent Cases of CRC in Japan (2019-2032)
Figure 36: Diagnosed Prevalent Cases of CC in IPF in Japan (2019-2032)
Figure 37: Patient Journey
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security